Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A synergistic antibiotic combination that pairs gentamicin (an aminoglycoside) with β-lactam antibiotics (such as penicillins, cephalosporins, or carbapenems). This combination leverages complementary mechanisms of action where β-lactams enhance bacterial cell wall permeability, facilitating gentamicin entry and uptake. Gentamicin binds to the 30S ribosomal subunit, disrupting protein synthesis and creating membrane fissures, while β-lactams inhibit cell wall synthesis. The combination demonstrates enhanced bactericidal activity against a wide range of pathogens, including resistant strains, and is particularly valuable for serious infections requiring rapid bacterial killing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gentamicin + β-lactam antibiotics.